Breaking News
March 21, 2019 - Smell of skin could lead to early diagnosis for Parkinson’s
March 21, 2019 - Difference in brain connectivity may explain autism spectrum disorder
March 21, 2019 - Untangling the microbiome — with statistics
March 21, 2019 - Human microbiome metabolites enhance colon injury by enterohemorrhagic E. coli, study shows
March 21, 2019 - Written media can improve citizens’ understanding of palliative care
March 21, 2019 - New research aims to find how asthma symptoms are aggravated
March 21, 2019 - New $9.7 million NIH grant project seeks to improve hearing restoration
March 21, 2019 - Researchers measure brain metabolite levels in people with mild memory problems
March 21, 2019 - FDA approves first drug for treatment of postpartum depression in adult women
March 20, 2019 - Gene editing and designer babies experiments face global moratorium
March 20, 2019 - Major scientific study of wound care dressings wins ‘Best Clinical or Preclinical Research Award’
March 20, 2019 - Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
March 20, 2019 - Big data study identifies drugs that increase risk of psychosis in youth with ADHD
March 20, 2019 - Mystery novel and dream spur key scientific insight into heart defect | News Center
March 20, 2019 - Study measures impact of policies designed to reduce air pollution in two mega-cities
March 20, 2019 - Mild sleep apnea during pregnancy changes sugar levels and may affect infant growth patterns
March 20, 2019 - SSB and Novasep collaborate to develop new membrane chromatography systems
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - New method based on neurofeedback may reduce anxiety
March 20, 2019 - Study explores whether alcohol consumption can have an effect on arthritis
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
March 20, 2019 - Androgen receptor plays vital role in regulating multiple mitochondrial processes
March 20, 2019 - NIH announces funding boost for Detroit Cardiovascular Training Program
March 20, 2019 - Study reveals another surgical option for patients with irreparable rotator cuff tears
March 20, 2019 - New robot-guided video game may be effective and low-cost solution for caregivers
March 20, 2019 - Heart Attacks Fall By One-Third Among Older Americans
March 20, 2019 - Data sharing uncovers five new risk genes for Alzheimer’s disease
March 20, 2019 - Does It Make Sense To Delay Children’s Vaccines?
March 20, 2019 - Lack of health insurance may increase Aging immigrants’ risk for cardiovascular disease
March 20, 2019 - Piece of puzzle unlocked in what drives alcohol addiction
March 20, 2019 - Researchers investigate whether Zika reservoirs are found in the Americas
March 20, 2019 - Compounds found in coffee may inhibit growth of prostate cancer
March 20, 2019 - Lab Innovations returns to the NEC on 30 & 31 October 2019
March 20, 2019 - How genes affect tobacco and alcohol use
March 20, 2019 - Osteoarthritis and rheumatoid arthritis have similar impacts on patients
March 20, 2019 - Individuals with infection history have higher risk of developing Sjögren’s syndrome
March 20, 2019 - Nursing home residents benefit from individualized multi-component exercise program
March 20, 2019 - Plant cellulose bone implants are “viable” option to support new bone growth, study finds
March 20, 2019 - Older people living in retirement communities benefit from improved health
March 20, 2019 - UTSA professor helps train first responders to detect prescription opioid overdoses
March 20, 2019 - Biohaven’s Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
March 20, 2019 - Smoking may limit body’s ability to fight dangerous form of skin cancer
March 20, 2019 - Researchers receive $9.7-million grant to develop new hearing-loss treatments for deaf
March 20, 2019 - TGen and ABL sign agreement to distribute new TB test technology
March 20, 2019 - UCD researchers lead development of new urine test to detect prostate cancer
March 20, 2019 - Miniature brains that can move muscles, grown in the lab
March 20, 2019 - Servier and Oncodesign announce research and drug development partnership
March 20, 2019 - FDA warns marketer of unapproved products claiming to treat addiction, chronic pain
March 20, 2019 - TB Medicine Pretomanid Enters Regulatory Review Process in the United States
March 20, 2019 - Breastfeeding can erase effects of prenatal violence for newborns
March 20, 2019 - Tens of Thousands of Heart Patients May Not Need Open-Heart Surgery
Study identifies possible new strategies to treat silent seizures in children

Study identifies possible new strategies to treat silent seizures in children

image_pdfDownload PDFimage_print

An unexpected brain region is important for Dravet Syndrome, finds study

As early as 3 months of age, infants with a severe form of epilepsy called Dravet syndrome start having convulsive seizures, during which their arms and legs jerk repeatedly. As they become toddlers, another type of seizure begins to appear. These seizures do not cause obvious convulsions, but disrupt consciousness and can occur more than 50 times every single day. A challenge to detect and difficult to treat, these non-convulsive seizures often go unnoticed by parents and physicians.

A recent study, published in the journal Cell Reports, characterizes these silent seizures in a mouse model of Dravet syndrome and identifies the brain area that could be targeted to stop them.

“We were able to pinpoint the exact spot in the brain that causes the seizures,” said Jeanne Paz, PhD, the senior author of the study, who is an assistant investigator at the Gladstone Institutes. “This discovery allowed us to develop two new strategies to prevent these non-convulsive seizures in mice simulating Dravet syndrome.”

By collaborating with Maria Roberta Cilio, MD, PhD, a renowned pediatric epileptologist at UC San Francisco, Paz confirmed that her findings are likely relevant to the human condition.

“If we could successfully eliminate non-convulsive seizures in children with Dravet syndrome, we could significantly improve their quality of life,” said Cilio, director of research at the UCSF Pediatric Epilepsy Center. “We could finally offer them the best conditions in which to reach their full potential.”

Nearly 8 in 10 patients with Dravet syndrome have a genetic mutation that causes both developmental delays and seizures, which can even lead to sudden death. Affected children also have cognitive deficits, sleeping difficulties and autism-like behaviors.

Identifying the Culprit

Neurons are highly specialized brain cells that send signals to one another, forming complex network that enable both basic and higher brain functions. When a neuron “fires,” it releases a signal that carries instructions for the receiving cell. While excitatory cells instruct the next cell to take action, inhibitory cells send signals to suppress the activity of receiving cells. Seizures are caused when excitatory cells function too strongly or inhibitory cells function too weakly–both of which result in too many cells in the brain getting excited at the same time.

Previous animal studies had shown that convulsive seizures are caused when inhibitory cells are not sufficiently active in a brain region called the cerebral cortex. Since then, the scientific field has focused on finding treatments to enhance the function of those cells.

Paz and her laboratory, on the other hand, study a different region of the brain: the thalamus. This region plays a major role in cognition, sleep, attention, and consciousness.

“All of these elements are altered in patients with Dravet syndrome in a way that is unlikely to be caused only by changes in the cerebral cortex,” explained Paz, who is also an assistant professor of neurology at UCSF. “We wanted to see what happens in this brain region and how its cells might be altered in the context of this syndrome.”

The researchers were expecting inhibitory cells in the thalamus to be less active, similarly to those in the cerebral cortex. Surprisingly, they saw the opposite.

“We found that the inhibitory cells in the thalamus were quite active in mouse models of Dravet syndrome,” said Stefanie Ritter-Makinson, PhD, one of the lead authors of the study and a former postdoctoral scholar in Paz’s laboratory.

Working closely with fellow lead author Alexandra Clemente-Perez, PhD, Ritter-Makinson used electroencephalography, or EEG, to record brain waves and detect abnormalities in brain activity in mice with Dravet syndrome. They also observed that these non-convulsive seizures were much more frequent than convulsive seizures, occurring hundreds of times each day in some mice.

That’s when Paz reached out to Cilio, an expert in the diagnosis and treatment of genetic epilepsies in young children, to confirm that equivalent seizures are seen in human patients.

“Maria Roberta confirmed that she witnesses the same types of seizures in her patients, and shared some human EEG recordings with us,” said Paz. “We compared the human and mouse recordings side by side, and we were surprised to see how closely they matched. We were encouraged that our work could translate to real people, so we went on to look for ways to stop the seizures.”

Two Strategies to Reduce Seizures

The non-convulsive seizures are in some cases called “atypical absence seizures.” Atypical, because they last longer–10 to 30 seconds on average–than those seen in children with typical absence epilepsy. Absence, because the patients appear as if they are mentally absent during the attacks, as they lose consciousness but without collapsing. Paz refers to these seizures as “silent” given that they can go unnoticed without an EEG recording.

When a child is experiencing an absence seizure, she or he will seem absent-minded, staring blankly into space. This can be perceived as the child not paying attention, but can have many detrimental effects in daily life.

“Imagine you have several 20-second blanks while I’m talking; you’ll get a sense of what I’m saying, but you won’t understand all of it,” explained Cilio. “Although they may not be as dramatic as convulsions, these interruptions can happen regularly throughout the day, so they really impair learning.”

Non-convulsive seizures in patients with Dravet syndrome are particularly difficult to treat compared to other types of seizures. Even the latest treatments are not effective in preventing or stopping them. For instance, cannabis-based drugs (for which Cilio is a leader) can reduce the number of convulsive seizures, but have little impact on the frequency of silent seizures.

In the new study, Paz identified two ways to stop non-convulsive seizures in mice.

First, she and her team manipulated the activity of specific neurons in the mouse brain using optogenetics, an approach that makes it possible to control the activity of neurons with laser light. They developed methods to detect seizures, and upon detection, quickly changed the activity of neurons in the thalamus to stop the seizures.

“This approach allowed us to identify the specific cells and brain activity required for initiating and aborting non-convulsive seizures in models of Dravet syndrome,” said Paz. “It had been difficult to do this in the past, because seizures involve a very large network of cells that ping-pong signals all around the brain within milliseconds. So, it was crucial for us to detect them immediately at their place of origin.”

Optogenetics cannot be used in humans yet, so Paz looked for a pharmacological drug that could achieve the same result. She found that a drug named EBIO1 reduced the firing of inhibitory cells in the thalamus. When Dravet model mice were treated with this drug, their seizures were markedly reduced and, in some cases, even stopped.

“It is very exciting that an FDA-approved drug already exists that targets the very brain activity we found to cause non-convulsive seizures,” said Paz. “To our knowledge, it has never been used in epilepsy, but no side effects were reported when it was used in clinical trials for movement disorders.”

When a drug has already been approved for safety by the US Food and Drug Administration (FDA), it can be made available to patients much more quickly.

Short-Term and Future Opportunities

The study by Paz and her team identified a drug that treats non-convulsive seizures through its action on the thalamus, and may explain why anti-seizure medications that do not reduce thalamic activity are not effective in stopping these seizures.

“Jeanne’s work identified a completely new target area in the brain for treating Dravet syndrome,” said Cilio. “Her study is an example of truly translational work, where a basic research effort could directly impact patients in the clinic.”

“We tried two different methods,” said Paz, “optogenetics could be an option for the future, while the drug could be made available to human patients soon.” “When I presented my findings recently at the American Epilepsy Society, some physicians expressed keen interest in testing this FDA-approved drug in the clinic.”

Paz added, “hopefully, this will be life-changing for these children.”

Source:

https://gladstone.org/about-us/press-releases/two-possible-new-ways-treat-silent-seizures-children

Tagged with:

About author

Related Articles